The Business Research Company’s Lonquex Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035
For oncology stakeholders and healthcare investors, the trajectory of the Lonquex market between 2026 and 2030 offers a window into how supportive cancer care is evolving. The Business Research Company’s latest forecast outlines a sector shaped by shifting treatment preferences, biosimilar competition, and a global rise in cancer diagnoses—factors that will determine how this critical therapy reaches patients.
Understanding the Lonquex Market Outlook Through 2030
The Lonquex market is poised for notable transformation between 2026 and 2030, driven by a combination of historical momentum and forward-looking demand. Past growth in this sector has been propelled by the rising adoption of chemotherapy regimens, improvements in hematology supportive care, early uptake of pegylated growth factors, enhanced cancer survival rates, and an expanding network of oncology treatment facilities. Looking ahead, the market is anticipated to build on this foundation, fueled by growing demand for long-acting supportive care medications, intensifying competition from biosimilars, a swelling cancer patient population, the proliferation of outpatient oncology services, and continuous innovation in hematopoietic growth factors.
Also worth a look: Alexander Hughes argues why human judgment still beats AI in cross-border executive search and Peck Training Group hits 30-year mark with 7,000 leaders trained worldwide.
Key Growth Factors Influencing Lonquex Market Expansion
A major catalyst for the Lonquex market is the growing preference for long-acting granulocyte colony-stimulating factor (G-CSF) therapies. This shift reflects a wider movement toward enhancing chemotherapy supportive care through more convenient, effective treatment options. At the same time, the market is adapting to an increasing focus on single-dose regimens, which improve patient adherence and ease the strain on healthcare systems.
Download a free sample of the lonquex market report:
https://thebusinessresearchcompany.com/sample_request?id=85503211&type=smp&name=Lonquex%20Market%20Report%202026&utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Nov_PR
Another significant force is the surge in biosimilar development programs. The expansion of biosimilars is redrawing the competitive map, spurring innovation and affordability in supportive cancer care. Additionally, there is a heightened focus on minimizing infection risks among chemotherapy patients, a critical factor driving product adoption and market growth in the years ahead.
What Lonquex Means in Cancer Care
Lonquex is the brand name for lipegfilgrastim, a long-acting form of granulocyte colony-stimulating factor designed to increase white blood cell production. It is commonly prescribed to manage severe neutropenia—a dangerous drop in neutrophils that frequently occurs in cancer patients receiving chemotherapy. Neutrophils are essential for defending the body against infections, and chemotherapy can impair their production by damaging bone marrow. Lonquex counteracts this effect, thereby reducing infection risks and enhancing patient outcomes during cancer treatment.
View the full lonquex market report:
https://thebusinessresearchcompany.com/report/lonquex-global-market-report?utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Nov_PR
Rising Cancer Incidence as a Market Driver for Lonquex
The climbing number of cancer cases globally is a primary factor expected to propel Lonquex market growth. Cancer incidence measures the count of newly diagnosed cases within a specific population over a defined period, typically expressed per 100,000 people annually. This uptick is tied to aging populations, lifestyle factors such as tobacco and alcohol use, environmental carcinogen exposure, genetic predispositions, and improved diagnostic capabilities. For example, in February 2024, the World Health Organization projected over 35 million new cancer cases worldwide by 2050, a 77% increase from roughly 20 million cases in 2022. This expanding patient pool underscores the urgent need for supportive care drugs like Lonquex.
The Role of Biosimilars in Accelerating Lonquex Market Growth
Biosimilars are biologic medicines that closely mirror approved reference products in safety, efficacy, and potency. The growth of biosimilars is expected to significantly boost the Lonquex market by enhancing treatment affordability and accessibility. Contributing factors include efforts to rein in healthcare costs, patent expirations of original biologics, rising prevalence of chronic diseases, and growing acceptance of biosimilars among healthcare providers and patients. Lonquex functions as a biosimilar by imitating natural granulocyte colony-stimulating factor activity, promoting neutrophil production, and preventing infections in chemotherapy patients. Abbott Laboratories reported in July 2025 that biosimilars have generated over $64 billion in savings for European healthcare systems to date, underscoring the financial impact that supports Lonquex market expansion.
Geographical Trends in the Lonquex Market
In 2025, North America held the largest share of the Lonquex market, thanks to advanced healthcare infrastructure and high adoption rates of innovative therapies. Meanwhile, the Asia-Pacific region is expected to see the fastest market growth during the forecast period. This acceleration is driven by rising cancer incidence, improving healthcare access, and expanding oncology services across Asia-Pacific countries. The Lonquex market report includes regional analysis covering Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, offering a global view of market dynamics.
Our 2026 market reports now feature expanded strategic intelligence through market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspots infographics, key technology and future trend analysis, along with updated graphics and tables.
Speak With Our Expert:
Saumya Sahay
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: marketing@tbrc.info
The Business Research Company – www.thebusinessresearchcompany.com
Follow Us On:
• LinkedIn: https://in.linkedin.com/company/the-business-research-company
Oliver Guirdham
The Business Research Company
+44 7882 955267
info@tbrc.info
Visit us on social media:
LinkedIn
Facebook
X
Why it matters: As global cancer incidence climbs toward the WHO’s projected 35 million new cases by 2050, the Lonquex market’s growth signals a broader shift toward more accessible, long-acting supportive care options. The dual forces of biosimilar savings—already exceeding $64 billion in Europe—and rising demand in Asia-Pacific highlight how cost-effective treatments are becoming central to oncology strategy worldwide.
